RESUMO
In response to increasing pressure on inpatient services and a meta-analysis indicating that cisplatin (C) is superior to carboplatin, we report a phase II trial of gemcitabine (G) and split-dose C in advanced non-small cell lung cancer (NSCLC) in an outpatient setting. Patients with stage IIIB/IV NSCLC received: G/C 1250/40 mg/m(2); G and C were given on day (d) 1 and d8 in a 21d cycle. Patients with performance status 0-2, adequate bone marrow function and calculated glomerular filtration rate (GFR) >50 ml/min were eligible. Forty-two patients were enrolled: 25 male; median age 62 (range 37-78) years. There were 26 patients (62%) with stage IV disease. One hundred and thirty-eight cycles of chemotherapy were delivered. Chemotherapy was well tolerated, allowing maintenance of planned dose intensity (DI) with mean dose delivered of 780.1 mg/m(2) (93%) and 25.6 mg/m(2) (96%) for G and C, respectively. The overall response rate was 43%. Median survival was 12.5 months with a median follow-up of 13.5 months. One year survival rate was 51%. G plus C both given on d1 and d8 (q21d) is a very active, well tolerated and convenient outpatient schedule, which maintains DI.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Adulto , Idoso , Assistência Ambulatorial , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Cisplatino/administração & dosagem , Cisplatino/efeitos adversos , Desoxicitidina/administração & dosagem , Desoxicitidina/efeitos adversos , Desoxicitidina/análogos & derivados , Feminino , Humanos , Neoplasias Pulmonares/mortalidade , Masculino , Pessoa de Meia-Idade , GencitabinaRESUMO
We report the case history of two patients treated with primary gastric irradiation for localized low-grade mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach that failed to respond to anti-Helicobacter pylori antibiotics. One patient refused gastrectomy and the other was considered unfit for surgery. Both patients obtained a biopsy-confirmed complete response and are well and disease free after a median follow-up time of 28 months. A review of the literature on the treatment options for this condition has been undertaken. Gastric irradiation is an effective and safe alternative to gastrectomy in the treatment of low-grade MALT lymphoma of the stomach with the added advantage of organ preservation.
Assuntos
Linfoma de Zona Marginal Tipo Células B/radioterapia , Neoplasias Gástricas/radioterapia , Idoso , Antibacterianos/uso terapêutico , Intervalo Livre de Doença , Gastrectomia , Infecções por Helicobacter/complicações , Helicobacter pylori/patogenicidade , Humanos , Linfoma de Zona Marginal Tipo Células B/patologia , Masculino , Pessoa de Meia-Idade , Neoplasias Gástricas/patologia , Resultado do TratamentoAssuntos
Braquiterapia , Radioisótopos do Iodo/uso terapêutico , Imageamento por Ressonância Magnética , Próstata/patologia , Neoplasias da Próstata/radioterapia , Humanos , Masculino , Próstata/diagnóstico por imagem , Neoplasias da Próstata/diagnóstico por imagem , Neoplasias da Próstata/patologia , UltrassonografiaRESUMO
Thymomas are the most common tumours of the anterior mediastinum; their clinical course is often complicated by accompanying autoimmune and paraneoplastic syndromes. Advanced malignant thymoma is particularly challenging to manage owing to the lack of evidence from randomised trials to guide treatment. Combination first-line chemotherapy has been trialled in several small studies and has been reported to produce a 50-80% response with platinum-containing regimes. Progression following first-line chemotherapy is difficult to manage as most of these patients maintain a good performance status and demand further active palliative treatment. There is no standard second-line treatment. We report a good clinical and radiological response to third-line palliative octreotide therapy in a patient who had a positive octreotide scan.
Assuntos
Antineoplásicos Hormonais/uso terapêutico , Octreotida/uso terapêutico , Timoma/tratamento farmacológico , Neoplasias do Timo/tratamento farmacológico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Cisplatino/administração & dosagem , Etoposídeo/administração & dosagem , Humanos , Ifosfamida/administração & dosagem , Masculino , Radiografia , Timoma/diagnóstico por imagem , Timoma/secundário , Neoplasias do Timo/diagnóstico por imagem , Resultado do TratamentoRESUMO
AIMS: Failure to carry out intracavitary brachytherapy (ICBT) in cervical carcinoma results in suboptimal chemoradiation and increases the risk of recurrence. The aim of this study was to investigate the role of adjuvant hysterectomy after unsuccessful ICBT. MATERIALS AND METHODS: A retrospective analysis was carried out of all women referred with cervical carcinoma between January 1999 and July 2007 where ICBT insertion was unsuccessful after the initial chemoradiation. The data collected and analysed included histology, stage of disease, causes for unsuccessful ICBT insertion, the response to the initial chemoradiation, subsequent treatment, morbidity, recurrence rates and survival rates. Kaplan-Meier and Log-rank methods were used to analyse recurrence-free and overall survival rates. RESULTS: ICBT insertion was unsuccessful in 19 of 208 (9%) patients. The causes of failure were: inability to dilate the cervix; uterine perforation; vesicovaginal fistula; patient refusal; other problems, including the presence of pyometrium, patient not fit for general anaesthetic, and narrow vagina; and consultant choice with no obvious reason. Fourteen of 19 patients (74%) received further pelvic external beam radiotherapy (EBRT) alone; five (26%) patients underwent adjuvant hysterectomy. The median follow-up for all patients was 63 months; 60 months for patients treated with adjuvant hysterectomy (range 31-68 months) and 85 months for patients treated with further EBRT. None of the patients treated with adjuvant hysterectomy developed any significant late toxicity. Seven patients (50%) treated with EBRT have relapsed compared with none in the adjuvant hysterectomy arm (P=0.068). Six patients (43%) in the EBRT arm have subsequently died of recurrent disease compared with none in the adjuvant hysterectomy arm (P=0.152). CONCLUSIONS: Adjuvant hysterectomy after unsuccessful ICBT does not seem to increase late toxicity and reduces the risk of pelvic recurrence and may improve survival. The role of adjuvant hysterectomy after suboptimal chemoradiation merits further investigation in clinical trials.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Braquiterapia , Carcinoma de Células Grandes/terapia , Carcinoma de Células Escamosas/terapia , Histerectomia , Recidiva Local de Neoplasia/prevenção & controle , Neoplasias do Colo do Útero/terapia , Adulto , Idoso , Carcinoma de Células Grandes/secundário , Carcinoma de Células Escamosas/secundário , Quimioterapia Adjuvante , Feminino , Humanos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Dosagem Radioterapêutica , Radioterapia Adjuvante , Estudos Retrospectivos , Taxa de Sobrevida , Fatores de Tempo , Resultado do Tratamento , Neoplasias do Colo do Útero/patologiaAssuntos
Neoplasias das Glândulas Suprarrenais/terapia , Feocromocitoma/terapia , 3-Iodobenzilguanidina/uso terapêutico , Neoplasias das Glândulas Suprarrenais/diagnóstico , Neoplasias das Glândulas Suprarrenais/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia Combinada , Humanos , Masculino , Pessoa de Meia-Idade , Feocromocitoma/diagnóstico , Feocromocitoma/secundárioRESUMO
Malignant transformation within a dermoid cyst is a rare event. The most common transformation is to squamous cell carcinoma. Patients are often elderly and present with advanced disease. The prognosis tends to be very poor. We present a case of locally invasive squamous cell carcinoma arising from a dermoid cyst in a 48-year-old lady. She underwent debulking surgery with no gross residual disease remaining. Within 2 months of the surgery she had recurrent disease and this was resistant to single agent carboplatin chemotherapy. She died 4 months after her initial surgery. We discuss the difficulties in diagnosing such tumours, the poor prognosis and review the various adjuvant treatment strategies that have been used in attempt to improve the outcome.